CARGO Therapeutic announced that it has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 ...

CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a ...

US clinical-stage biotech CARGO Therapeutics’ shares plummeted more than 75% to $3.23 yesterday, after it announced that it ...

Shares of CARGO Therapeutics , Inc. (NASDAQ:CRGX) plummeted 75% following the company's decision to discontinue its Phase 2 ...

SAN CARLOS, Calif. - CARGO Therapeutics , Inc. (NASDAQ:CRGX), a clinical-stage biotech company currently valued at $628 ...

CAR T–focused biotech Cargo Therapeutics surprised and disappointed analysts when it announced that it would discontinue a ...

The changes will extend the company's cash runway, enabling it to advance a tri-specific CAR T-cell candidate and its allogeneic cell therapy platform.

CARGO Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CRGX ...

CRGX Investors Have Opportunity to Join CARGO Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm ...

Detailed price information for Cargo Therapeutics Inc (CRGX-Q) from The Globe and Mail including charting and trades.